Technology | 2017.03.20
PARI Pharma development featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) is licensed to Breath Therapeutics
STARNBERG, Germany, March 20, 2017 /PRNewswire/ -- PARI Pharma, a company focused on optimization of drug-device combinations, has licensed its first-in-class inhalation development program for Bronchiolitis Obliterans Syndrome (BOS) to Breath Therapeutics GmbH (Breath Therapeutics,...
For more information, please visit
http://www.prnewswire.com/news-releases/[...]th-therapeutics-300426063.html
